P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.
Ajay K. Nooka,Philippe Moreau,Saad Z. Usmani,Alfred L. Garfall,N. W. C. J. van de Donk,Jesús F. San Miguel,A. Oriol Rocafiguera,Ajai Chari,Lionel Karlin,Maria-Victoria Mateos,Rakesh Popat,Joaquín Martínez,Surbhi Sidana,D. Trancucci,Raluca I. Verona,Suzette Girgis,Clarissa M. Uhlar,Tara Stephenson,Arnob Banerjee,Amrita Krishnan +19 more
TL;DR: Current data with ̃9 months of follow-up reaffirm the deep and durable responses that have been observed with tec in pts with highly refractory MM, with no new safety signals.
Journal ArticleDOI
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
Hartmut Goldschmidt,Philippe Moreau,Heinz Ludwig,Ruben Niesvizky,Wee Joo Chng,Douglas E. Joshua,Katja Weisel,Andrew Spencer,Robert Z. Orlowski,Shibao Feng,Karim Iskander,Meletios A. Dimopoulos +11 more
TL;DR: Overall, Kd was superior to Vd in RRMM regardless of route of bortezomib administration or prior bortrazomib exposure, and response rates were higher for Kd versus retreatment with bortzomib (SC or IV Vd) and in bortazomib naive patients.
Journal ArticleDOI
New insights in the treatment of patients with solitary bone plasmacytoma.
Kayane Mheidly,Thierry Lamy De La Chapelle,Mathilde Hunault,Lotfi Benboubker,Mohamed Benchalal,Philippe Moreau,Alix Baugier de Materre,Olivier Decaux,Kamel Laribi +8 more
TL;DR: Kayane Mheidly, Thierry Lamy De La Chapelle, Mathilde Hunault, Lotfi Benboubker, Mohamed Benchalal, Philippe Moreau, Alix Baugier de Materre, Olivier Decaux and Kamel Laribi
Journal ArticleDOI
Infection fusariale chez le neutropénique: à propos de trois observations
TL;DR: In this article, trois cases d'infection fusariale survenue chez des patients neutropeniques porteurs d'une hemopathie are reported.
Journal ArticleDOI
Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04.
Cyrille Touzeau,Aurore Perrot,Cyrille Hulin,Salomon Manier,Margaret Macro,Denis Caillot,Lionel Karlin,Olivier Decaux,Caroline Jacquet,Mourad Tiab,Xavier Leleu,Lucie Planche,Hervé Avet-Loiseau,Philippe Moreau +13 more
TL;DR: Dara-KRD as induction prior ASCT is safe and allows deep responses in TE NDMM patients with high-risk cytogenetic profile, and longer follow-up is needed to evaluate safety and efficacy of the overall strategy.